权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cardiac Regeneration with Bioengineered Human Stem Cells

利用生物工程人类干细胞进行心脏再生

基本信息

批准号：
9123170
负责人：
Young-Sup Yoon
金额：
$ 39万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9123170
关键词：
Affect Alabama Antibodies Autologous Biocompatible Materials Biomedical Engineering Cardiac Cardiac Myocytes Cardiovascular system Cell Maturation Cell Survival Cell Therapy Cell Transplants Cells Choristoma Defect Disease Echocardiography Endothelial Cells Engineering Engraftment Ethics Extracellular Matrix Fibroblasts Functional disorder Gel Genes Goals Growth Heart Heart failure Human Human Engineering Image Immunologics In Vitro Laboratories Magnetic Resonance Imaging Messenger RNA Methods Mitochondria Modeling Molecular Morbidity - disease rate Mus Myocardial Myocardial Infarction Myocardial Ischemia Myocardium Myosin Heavy Chains Peptides Pluripotent Stem Cells Population Population Heterogeneity Protocols documentation Publishing Research Personnel Risk Role Source Specificity Stem cells Supporting Cell Techniques Technology Teratoma Therapeutic Effect Therapeutic Uses Transplantation Tumor Tissue Undifferentiated United States Universities Vascularization Ventricular Ventricular Function Virus Work base cardiac regeneration cardiac repair cell behavior cell type cellular engineering clinical application embryonic stem cell expectation human embryonic stem cell human stem cells induced pluripotent stem cell injured insight microCT mortality nanoscale nanostructured new technology novel novel strategies peptidomimetics public health relevance repaired research study stem cell therapy

项目摘要

DESCRIPTION (provided by applicant): Human pluripotent stem cells (hPSCs), which include embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), offer unprecedented promise for cardiac repair; however, many hurdles must be overcome before clinical application is possible. Current methods for differentiating cardiomyocytes (CMs) from hPSCs result in heterogeneous populations of cells, including undifferentiated or non-CM cells, which may pose a risk for tumor or aberrant tissue formation. For therapeutic use, ventricular CMs (vCMs) are ideal because vCMs are the most extensively affected cell type in myocardial infarction and the major source for generating cardiac contractile forces. Although various strategies have been attempted for CM enrichment, these strategies have drawbacks in terms of purity or specificity. We recently developed a novel technology to purify CMs by targeting CM-specific intracellular mRNAs using molecular beacons (MBs), which will enable isolation of the desired CMs for use in therapy. Another obstacle to cell therapy is low retention of transplanted cells in injured myocardium. To overcome this problem, engineering of CMs with biomaterials or co-transplantation with other cells has been attempted. My co-investigator and I have been working to develop technologies for engineering cardiovascular cells with peptide amphiphile (PA)-based nanostructured biomaterials for enhancing the effects of cell therapy. The goal of this proposal is to develop a strategy for cardiac repair with hPSC-derived vCMs by two novel approaches: to purify hPSC-derived vCMs with MBs and to engineer these CMs with self-assembled nanomatrix gels and other cells including hPSC-derived ECs and fibroblasts. In aim 1, we seek to purify vCMs from differentiating hPSCs using specific MBs. In aim 2, we will engineer purified hPSC-derived CMs, hPSC-derived ECs and other supportive cells with extracellular matrix-mimicking self-assembled nanomatrix gel which contains growth factors to enhance cell viability, vascularization, and cell maturation, and determine the optimal cell- nanomatrix constructs. In aim 3, we will determine the therapeutic effects of engineered hPSC- derived cardiovascular cell constructs on injured myocardium and elucidate the underlying mechanisms. We anticipate that the results of the proposed experiments will yield new insight into the role of novel stem cell therapy for cardiac repair.